医学
噻嗪
指南
血管紧张素受体阻滞剂
血压
重症监护医学
内科学
药物治疗
血管紧张素转换酶
心脏病学
病理
作者
Christopher W. Ives,Suzanne Oparil
出处
期刊:The Lancet
[Elsevier BV]
日期:2019-10-24
卷期号:394 (10211): 1782-1784
被引量:4
标识
DOI:10.1016/s0140-6736(19)32461-4
摘要
Following the new definition in the 2017 American College of Cardiology/American Heart Association hypertension guideline, 103·3 million adults in the USA now have hypertension.1 The majority of these people are candidates for pharmacological antihypertensive therapy. Health-care providers faced with the question of which medication to prescribe first for newly diagnosed patients get little help from current hypertension guidelines. These guidelines recommend multiple first-line drug classes, including thiazide or thiazide-like diuretics (THZs), angiotensin converting-enzyme inhibitors (ACEis), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs),2,3 and, in some cases, β blockers.
科研通智能强力驱动
Strongly Powered by AbleSci AI